SaadiCorp
An editor has nominated this article for deletion. You are welcome to participate in the deletion discussion, which will decide whether or not to retain it. |
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Company type | Private |
|---|---|
| Industry | Research, Healthcare |
| Founded | 2019 |
| Headquarters | Lahore, Pakistan. |
Key people |
|
Number of employees | ≈ 11 (August 2024) |
| Website | saadicorp |
Saadi Corporation Limited (commonly known as SaadiCorp) is a research institute based in Lahore, Pakistan, that specialises in leveraging artificial intelligence (AI) to drive advancements in healthcare research.[1] The company is primarily dedicated to developing innovative solutions for personalized medicine, with a key focus on the early diagnosis, treatment, and management of thyroid cancer. SaadiCorp's mission is to integrate cutting-edge technology with medical expertise to improve patient outcomes and contribute to the global healthcare landscape.[2]
Since its inception in 2019, SaadiCorp has made significant contributions to the medical field through a variety of initiatives. The company collaborates with leading hospitals and research centre to sponsor clinical trials, support research fellowships, and develop AI-powered systems aimed at improving early detection methods, diagnostic accuracy, and personalized treatment plans for thyroid cancer.
SaadiCorp's research efforts are driven by its commitment to addressing the challenges of thyroid cancer, which remains one of the most prevalent endocrine malignancies. The company has invested over PKR 9.5 million in thyroid cancer research, funded over 10 clinical trials, and supported 15 research fellowships to explore novel therapies and methods for early detection.
This research is conducted in close collaboration with the Cancer Care Hospital & Research Centre,[3][failed verification] and aims to reduce the high rate of underdiagnosed cases in Pakistan.
Through its AI-driven research, SaadiCorp is working on predictive models and genomic analysis tools that assist in identifying high-risk patients early on. By combining artificial intelligence with traditional medical practices, the company seeks to revolutionize the way healthcare providers approach thyroid cancer diagnosis and treatment.
History
[edit]SaadiCorp was established in 2019 by Muhammad Salman Saadi under the name AGCN (pvt) ltd. It started off as a taxation and accounting firm but soon fell into troubles with the Federal Board of Revenue (FBR).[4][5] Due to this, Salman Saadi's role in the company got limited to an accounts officer.[6] In 2023, the company got renamed to "Saadi Taxation and Accounting Corporation" and sold its digital assets and name trademark of AGCN to a private seller and in late 2023, Naveed Khalid acquired a 75% ownership stake in the company and took over as Chairman. This acquisition marked the company's expansion into AI and healthcare research, especially in the field of thyroid cancer. By this time, Saadi Taxation and Accounting Corporation got renamed to Saadi Corporation Limited (or SaadiCorp).
Healthcare research
[edit]SaadiCorp's core research efforts are centered around thyroid cancer. The company has collaborated with medical institutions such as the Cancer Care Hospital & Research Centre to improve early diagnosis and develop novel treatment methods. The company has invested over PKR 9.5 million into research projects aimed at advancing early detection techniques, predictive models, and AI-driven therapies for thyroid cancer.
Thyroid Oncogenomics Research Paper (28/08/2024)
[edit]On the 28th of August, 2024, SaadiCorp submitted a research paper to the journal Oncogenesis, published by the Nature Portfolio. The paper was titled Identification of Novel Genetic Biomarkers for Early Detection of Thyroid Cancer Using AI-Enhanced Genomic Profiling. This research identified several novel genetic biomarkers with a high prevalence in thyroid cancer samples, significantly distinguishing them from controls. These biomarkers demonstrated strong potential for early detection, with AI playing a critical role in their discovery by revealing complex genetic interactions. Validation studies further confirmed the biomarkers' effectiveness, showing promising sensitivity and specificity for clinical application.[7]
Ownership and leadership
[edit]As of 2023, Naveed Khalid holds a 99% ownership stake in SaadiCorp and serves as the CEO of the company. The original founder, Muhammad Salman Saadi, previously held the role of CEO but stepped down following the change in ownership. The company's headquarters are located in Lahore, Punjab, Pakistan.
References
[edit]- ^ how a pakistani ai startup is revolutionizing healthcare
- ^ saadicorp.ltd
- ^ cancer care hospital and research centre
- ^ https://www.fbr.gov.pk/Events/final-showcause-notice-to-ms-agcn-pakistan-a/132101
- ^ https://urdu.fbr.gov.pk/Events/final-showcause-notice-to-ms-agcn-pakistan-a/132101
- ^ http://pprasindh.gov.pk/evaluation/801EV1680912422ITDept140514.pdf
- ^ saadicorp thyroid oncogenomics research paper (28/08/2024)